Merck sells off eye drugs and Colorado manufacturing unit
This article was originally published in Scrip
Executive Summary
Merck & Co is getting rid of an assortment of ophthalmic assets in a $600m+ deal and shedding its manufacturing facility in Colorado – just two weeks after the sale of its consumer business to Bayer for $14.2bn.